Nephrocare Health Services: Robust Q1 FY27 Performance

Nephrocare Health Services Ltd. announced its Q1 FY27 financial results, reporting a 23.7% increase in revenue to INR 282 crore, up from INR 228 crore in Q1 FY26. Adjusted EBITDA grew by 31.0% to INR 65.1 crore, and Adjusted Profit After Tax (PAT) surged by 41.7% to INR 37 crore.

Reader Takeaway: Strong revenue growth and margin expansion driven by aggressive expansion and international business. Watch Saudi tender timelines and capital deployment.

What just happened

In the first quarter of FY27, Nephrocare Health Services Ltd. posted a revenue of INR 282 crore, marking a 23.7% year-on-year increase. The company's operational efficiency and strategic expansion contributed to a 31.0% rise in Adjusted EBITDA to INR 65.1 crore, and a 41.7% jump in Adjusted PAT to INR 37 crore.

Why this matters

The results indicate sustained growth driven by operational improvements and network expansion. An expanded Adjusted EBITDA margin of 23.1% and improved PAT margin to 13.1% highlight the company's increasing profitability. The continued growth in treatments and active guests, coupled with expansion in the Philippines and India, underpins the company's market position.

The backstory

Nephrocare Health Services is a pure-play dialysis service provider. The company has been focusing on scaling its operations through network expansion and international diversification. It has utilized a significant portion of its IPO proceeds for this growth.

What changes now

The company is set to continue its aggressive expansion, aiming for a 15-20% CAGR over the next three to five years. Key growth levers include increasing guest volumes, expanding its clinic footprint in India and internationally, and entering new countries. The company also aims to grow its contribution from international operations, which already stand at 45% of total revenue.

Risks to watch

Progress in Saudi Arabia is contingent on government tender releases, which have unpredictable timelines. Aggressive capital deployment for expansion and acquisitions needs to be managed efficiently to maintain Return on Capital Employed (ROCE), which was 21% in Q1. The dialysis business inherently requires higher working capital, although the company has improved its accounts receivable days.

Peer comparison

Nephrocare Health operates in a space where traditional hospital-operated dialysis units are often non-core. As a pure-play network, it aims to scale by outsourcing these operations, positioning itself to benefit from the organized shift in the Indian dialysis market.

Context metrics (time-bound)

Revenue per treatment (RPT) increased by 9.2% to INR 2,733. Treatments grew by 13.3% to 10.3 lakh. Active guests increased by 13.0% to 38,262. International operations contribute 45% of revenue, with 7 new clinics opened in the Philippines. India saw 19 new clinics, totaling 550 clinics across 357 cities in 5 countries. 68% of IPO proceeds (INR 207 crore) have been utilized.

What to track next

Investors will be watching the timeline for Saudi Arabian tenders, the pace of international market entry, and the company's ability to manage its working capital and capital allocation effectively to sustain profitability during its expansion phase.